Key facts
- Crystalys Therapeutics’s last known valuation is $263.0M (Sep 2025).
- It has raised $205.0M; the latest was Early Stage VC ($205.0M) in Sep 2025.
- Notable investors include KB Investment, Alexandria Venture Investments, Novo Holdings, Perceptive Advisors, SR One Capital Management — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Crystalys Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Crystalys Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Crystalys Therapeutics
Developer of innovative therapeutics designed to address the significant unmet medical needs of people living with gout. The company offers advanced research capabilities and clinical trial development to access new treatment options that improve quality of life, enabling patients with gout to access improved therapeutic options.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2025
- Employees
- 16
- Website
- crystalystx.com/
- Ownership
- Privately Held (backing)
Crystalys Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Crystalys Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Crystalys Therapeutics in its N-PORT filings yet. We sweep new filings monthly.